– Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASCO Annual Meeting as a late-breaking oral presentation on June 3rd – – Company to host a conference call on June 3rd following the PRGN-2012 ASCO presentation to discuss in detail the pivotal study results and provide business updates – – PRGN-2012 rolling BLA submission, under an accelerated approval pathway, is anticipated in the second half of 2024; commercial re ...

Precigen, Inc. (NASDAQ:PGEN) Q4 2023 Earnings Conference Call March 19, 2024 4:30 PM ET Company Participants Steve Harasym - Vice President, Investor Relations Helen Sabzevari - President & Chief Executive Officer Harry Thomasian - Chief Financial Officer Jim Shaffer - Head of our Commercial Conference Call Participants Jason Butler - Citizens JMP Jennifer Kim - Cantor Fitzgerald Swayampakula Ramakanth - H.C. Wainwright Brian Cheng - JPMorgan Operator Good afternoon and welcome to the Precigen Full-Year 202 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36042 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 26-0084895 (State or other jurisdiction ...

Exhibit 99.1 Precigen Reports Full Year 2023 Financial Results and Business Updates GERMANTOWN, MD, March 19, 2024 – Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced full year 2023 financial results and business updates. "2024 is poised to be a transformative year for Precigen, as we are on track to present pivotal Phase 2 data in the second quarter and submit a BLA for PRGN-2012 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Virginia 26-0084895 (State or other jurisdiction of incorporation or organization) For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36042 PRECIGEN, INC. (Exact nam ...

Precigen, Inc. (NASDAQ:PGEN) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Steve Harasym - Vice President, Investor Relations Helen Sabzevari - President & Chief Executive Officer Harry Thomasian - Chief Financial Officer Conference Call Participants Jason Butler - JMP Securities Jennifer Kim - Cantor Fitzgerald Arthur He - H.C. Wainwright Ben Burnett - Stifel Brian Cheng - JPMorgan Operator Good morning and welcome to the Precigen Second Quarter and First Half 2023 Financi ...

PART I - FINANCIAL INFORMATION [Item 1. Condensed Consolidated Financial Statements](index=5&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements) The company's unaudited statements show a Q2 2023 net loss of $20.3 million and increased shareholders' equity [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to $207.5 million while shareholders' equity rose to $166.2 million due to debt retirement Condensed Consolidated Balance Sheet Data (in thousands) | Account | June 30, 2023 | December 31, 2022 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $16,546 | $4,858 | | Short-term investments | $71,888 | $51,092 | | Total current assets | $105,632 | $118,159 | | Total assets | $207,527 | $215,977 | | **Liabilities & Shareholders' Equity** | | | | Total current liabilities | $30,773 | $78,645 | | Total liabilities | $41,317 | $89,718 | | Total shareholders' equity | $166,210 | $126,259 | | Total liabilities and shareholders' equity | $207,527 | $215,977 | [Condensed Consolidated Statements of Operations](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) The company reported a Q2 2023 net loss of $20.3 million on revenues of $1.8 million Statement of Operations Highlights (in thousands, except per share data) | Metric | Q2 2023 | Q2 2022 | H1 2023 | H1 2022 | | :--- | :--- | :--- | :--- | :--- | | Total revenues | $1,767 | $2,911 | $3,618 | $8,424 | | Research and development | $11,874 | $11,954 | $24,037 | $23,755 | | Selling, general and administrative | $9,316 | $12,670 | $20,954 | $26,359 | | Operating loss | ($21,120) | ($24,162) | ($44,597) | ($46,315) | | Net loss | ($20,319) | ($17,635) | ($43,053) | ($36,886) | | Net loss per share, basic and diluted | ($0.08) | ($0.09) | ($0.18) | ($0.18) | [Condensed Consolidated Statements of Cash Flows](index=11&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operations was $34.2 million, while financing activities provided $29.6 million from a stock offering Cash Flow Summary (in thousands) | Activity | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 | | :--- | :--- | :--- | | Net cash used in operating activities | ($34,156) | ($25,836) | | Net cash (used in) provided by investing activities | ($26,905) | $33,141 | | Net cash provided by (used in) financing activities | $29,589 | ($276) | | Net decrease in cash, cash equivalents, and restricted cash | ($31,644) | $6,558 | - In January 2023, the company received **net proceeds of $72.8 million** from a public offering of common stock[38](index=38&type=chunk)[100](index=100&type=chunk) - The company **retired $43.1 million** of its Convertible Notes during the first six months of 2023[38](index=38&type=chunk)[95](index=95&type=chunk) [Notes to the Condensed Consolidated Financial Statements](index=13&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements) Notes detail key events including a subsidiary sale, debt retirement, a $72.8 million stock offering, and a lawsuit settlement - Management believes existing liquid assets will allow the company to **continue operations for at least one year** from the financial statement issuance date, despite expecting continued operating losses[45](index=45&type=chunk) - In August 2022, the company completed the **sale of its subsidiary, Trans Ova, for $170 million** plus potential earn-outs, with results reported as discontinued operations[62](index=62&type=chunk)[147](index=147&type=chunk) - On June 30, 2023, the company repurchased all remaining outstanding Convertible Notes, retiring a total of **$43.34 million in principal** during H1 2023[92](index=92&type=chunk)[95](index=95&type=chunk) - In January 2023, the company closed a public offering of 43.96 million shares, resulting in **net proceeds of $72.8 million**[100](index=100&type=chunk) - The company reached an agreement to **settle a shareholder class action lawsuit for $13.0 million**, for which an accrual has been recorded[116](index=116&type=chunk)[117](index=117&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=30&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses decreased revenue, lower operating expenses, and sufficient liquidity following a recent equity offering [Overview](index=30&type=section&id=Overview) Precigen is a clinical-stage biopharmaceutical company developing gene and cell therapies across two operating segments - The company is advancing lead clinical programs including **PRGN-3005, PRGN-3006, and PRGN-3007** (UltraCAR-T platform), and **PRGN-2009 and PRGN-2012** (AdenoVerse platform)[132](index=132&type=chunk) - **PRGN-2012** for recurrent respiratory papillomatosis (RRP) has received **Breakthrough Therapy Designation** from the FDA[138](index=138&type=chunk) - The company's reportable segments are **Biopharmaceuticals** (Precigen and ActoBio) and **Exemplar** (research models and services)[135](index=135&type=chunk)[148](index=148&type=chunk) [Results of Operations](index=35&type=section&id=Results%20of%20Operations) Q2 2023 revenues fell 39% year-over-year, while a 27% drop in SG&A expenses helped narrow the operating loss Q2 2023 vs Q2 2022 Performance (in thousands) | Metric | Q2 2023 | Q2 2022 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Total revenues | $1,767 | $2,911 | ($1,144) | (39.3)% | | Research and development | $11,874 | $11,954 | ($80) | (0.7)% | | Selling, general and administrative | $9,316 | $12,670 | ($3,354) | (26.5)% | | Operating loss | ($21,120) | ($24,162) | $3,042 | (12.6)% | H1 2023 vs H1 2022 Performance (in thousands) | Metric | H1 2023 | H1 2022 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Total revenues | $3,618 | $8,424 | ($4,806) | (57.1)% | | Research and development | $24,037 | $23,755 | $282 | 1.2% | | Selling, general and administrative | $20,954 | $26,359 | ($5,405) | (20.5)% | | Operating loss | ($44,597) | ($46,315) | $1,718 | (3.7)% | - The decrease in SG&A expenses was primarily driven by a **reduction in professional fees of $2.2 million for Q2 and $4.2 million for H1**, mainly due to lower legal fees[168](index=168&type=chunk)[181](index=181&type=chunk) [Liquidity and Capital Resources](index=39&type=section&id=Liquidity%20and%20Capital%20Resources) The company holds $16.5 million in cash and believes its liquid assets are sufficient for the next 12 months - As of June 30, 2023, the company had **cash and cash equivalents of $16.5 million** and **investments of $79.0 million**[189](index=189&type=chunk) - The company raised **$72.8 million in net proceeds** from a public stock offering in January 2023[190](index=190&type=chunk) - Management believes existing liquid assets will fund operating expenses and capital requirements for **at least the next 12 months**[199](index=199&type=chunk) - Future funding may be sought through equity offerings, debt financing, or strategic alliances, which could lead to **dilution or relinquishing valuable rights**[201](index=201&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=42&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk is interest rate fluctuation on its $95.6 million investment portfolio - The company's investment portfolio, valued at **$95.6 million** as of June 30, 2023, is exposed to interest rate risk[211](index=211&type=chunk) - The company believes a **100 basis point increase in interest rates would not have a material effect** on the fair value of its interest-sensitive financial instruments[211](index=211&type=chunk) [Controls and Procedures](index=43&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of June 30, 2023 - Management, including the CEO and CFO, concluded that **disclosure controls and procedures were effective** as of the end of the reporting period[213](index=213&type=chunk) - **No material changes** to internal control over financial reporting occurred during the three months ended June 30, 2023[214](index=214&type=chunk) PART II - OTHER INFORMATION [Item 1. Legal Proceedings](index=44&type=section&id=Item%201.%20Legal%20Proceedings) Management believes ongoing legal matters will not have a material adverse effect on the company's business - The company does not believe that any ongoing legal matters will have a **material adverse effect** on its business, financial condition, or cash flows[217](index=217&type=chunk) - For further details on legal matters, the report refers to **Note 14** of the Condensed Consolidated Financial Statements[218](index=218&type=chunk) [Item 1A. Risk Factors](index=44&type=section&id=Item%201A.%20Risk%20Factors) No material changes to risk factors have occurred since the company's last Annual Report on Form 10-K - **No material updates or changes** to risk factors have occurred since the filing of the company's Annual Report[219](index=219&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=44&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities during the reporting period - None[221](index=221&type=chunk) [Item 6. Exhibits](index=45&type=section&id=Item%206.%20Exhibits) This section lists filed exhibits, including an amended license agreement and required CEO/CFO certifications - An **Amended and Restated Exclusive License Agreement with Alaunos Therapeutics**, dated April 3, 2023, was filed as an exhibit[226](index=226&type=chunk)

Call Start: 08:00 January 1, 0000 9:01 AM ET Precigen, Inc. (NASDAQ:PGEN) Q1 2023 Earnings Conference Call May 10, 2023 08:00 ET Company Participants Steve Harasym - Vice President, Investor Relations Helen Sabzevari - President & Chief Executive Officer Harry Thomasian - Chief Financial Officer Conference Call Participants Jason Butler - JMP Securities Jennifer Kim - Cantor Fitzgerald Carolina Ibanez Ventoso - Stifel Arthur He - H.C. Wainwright Operator Good morning and welcome to the Precigen First Quarte ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36042 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 26-0084895 (State or other jurisd ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36042 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 26-0084895 (State or other jurisdiction ...